Middle East Journal of Cancer

Updates on Peritoneal Surface Malignancy Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy Morbidity and Mortality Outcomes from the Shiraz Surgical Oncology Group

Document Type : Brief Report(s)

Authors

Majid Akrami
Mohammad Yasin karami

Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

https://doi.org/10.30476/mejc.2024.103256.2131
Abstract
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are well-known in the treatment of different types of peritoneal carcinomatosis (PC). CRS and HIPEC are associated with several major comorbidity and can affect patients short-term and long-term outcomes. The present study aimed to evaluate the short term follow up, mortality and morbidity rate of CRS and HIPEC of recent period surgery compared with our previously reported study patients.
Method: Short-term follow-up data were collected and analyzed for 150 PC patients who underwent CRS-HIPEC between 2017 and 2021 compared with 43 patients from our retrospective cohort study. Data were analyzed using SPSS 23. The statistical significance was determined by a P-value < 0.05.
Results: Mortality at 60 days of the 2017-2021 group and the 2016 group was 1.33% (2/150) and 7 % (3/43), respectively. The 2017-2021 group showed less minor and major complications according to Clavien-Dindo classification. Overall, the mortality and morbidity rates were lower as compared with our previous reported study.
Conclusion: Our center has achieved an acceptable and progressive route through the use of CRS and HIPEC for PC, as demonstrated by our study.

Highlights

Majid Akrami (Google Scholar)

Mohammad Yasin karami (Google Scholar)

Keywords

Peritoneal neoplasms
Cytoreductive surgery
Chemotherapy
Morbidity
Mortality
Subjects

How to cite this article:

Akrami M, karami MY. Updates on Peritoneal Surface Malignancy Cytoreductive and Hyperthermic Intraoperative Peritoneal Chemotherapy Morbidity and Mortality Outcomes from the Shiraz Surgical Oncology Group. Middle East J Cancer. 2025;16(4):366-71. doi: 10.30476/mejc.2024.103256.2131.

 

  1. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573-85. doi: 10.1016/j.jamcollsurg.2013.12.013. PMID: 24491244; PMCID: PMC3965636.
  2. Hotza G, Karageorgos M, Pastourmatzi V, Baniowda N, Kyziridis D, Kalakonas A, et al. Morbidity and mortality of patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Discov Oncol. 2024;15(1):106. doi: 10.1007/s12672-024-00968-4. PMID: 38580760; PMCID: PMC10997575.
  3. Allievi N, Sidhom M, Samuel MV, Tzivanakis A, Dayal S, Cecil T, et al. Survival analysis and recurrence patterns in 555 patients with colorectal peritoneal metastases treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [ahead of print] Ann Surg Oncol. 2024. doi: 10.1245/s10434-024-15942-1. PMID: 39128977.
  4. Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B. Advanced pseudomyxoma peritonei requiring gastrectomy to achieve complete cytoreduction results in good long-term oncologic outcomes. Ann Surg Oncol. 2016;23(13):4316-21. doi: 10.1245/s10434-016-5389-7. PMID: 27380645.
  5. Acs M, Babucke M, Jusufi M, Kaposztas Z, Slowik P, Hornung M, et al. Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Innov Surg Sci. 2024;9(1):3-15. doi: 10.1515/iss-2023-0055. PMID: 38826635; PMCID: PMC11138857.
  6. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230-40.  doi: 10.1056/NEJMoa1708618. PMID: 29342393
  7. Harper MM, Kim J, Pandalai PKJJocm. Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med. 2022;11(10):2840. doi:10.3390/jcm11102840. PMID: 35628966; PMCID: PMC9143396.
  8. Akrami M, Khezri S, Tahmasebi S, Karami MY, Shiravani Z, Zangouri V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: Initial report from Shiraz Surgical Oncology Group. Middle East J Cancer. 2022; 13(3):458-65. doi: 10.30476/mejc.2021.87830.1440.
  9. Mielko J, Rawicz-Pruszyński K, Sędłak K, Gęca K, Kwietniewska M, Polkowski WPJC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: learning curve based on surgical and oncological outcomes. Cancers (Basel). 2020; 12(9):2387. doi: 10.3390/cancers12092387. PMID: 32842535.
  10. Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007; 14:2270-80. doi: 10.1245/s10434-007-9406-8. PMID: 17464543.
  11. Kusamura S, Baratti D, Hutanu I, Rossi P, Deraco M. The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am. 2012;21(4):559-76. doi: 10.1016/j.soc.2012.07.011. PMID: 23021716
  12. Smeenk R, Verwaal V, Zoetmulder F. Learning curve of combined modality treatment in peritoneal surface disease. Br J Sug. 2007;94(11):1408-14. doi: 10.1002/bjs.5863. PMID: 17631678.
  13. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900-7. doi: 10.1097/SLA.0b013e3181a45d86. PMID: 19474692.
  14. Mohamed F, Moran B. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J. 2009;15(3):196-9. doi: 10.1097/PPO.0b013e3181a58d56. PMID: 19556904.
  15. Li Y, Yu Y, Liu Y. Report on the 9(th) International Congress on Peritoneal Surface Malignancies. Cancer Biol Med. 2014 Dec;11(4):281-4. doi: 10.7497/j.issn.2095-3941.2014.04.008. PMID: 25610715; PMCID: PMC4296089.
  16. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. doi: 10.1093/annonc/mdw235. PMID: 27380959.
  17. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018; 29(1):44-70. doi: 10.1093/annonc/mdx738. PMID: 29155929.
  18. Nikeghbalian S, Nikoupour H, Dehghani M, Karami MY, Hemati RJAoIM. Cytoreductive surgery and hyperthermic intraoperative chemotherapy for management of peritoneal carcinomatosis. Arch Iran Med. 2018;21(4):158-63. PMID: 29693406.
  19. Farzaneh F, Ashtiani AJ, Bohlooli M, Hosseini MS. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: A 2-year survival analysis study. Curr Women's Health Rev. 2024;20(4):121-30.doi: 10.2174/1573404820666230822145758.
  20. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013:978394. doi: 10.1155/2013/978394. PMID: 23710154; PMCID: PMC3654240
  21. Wu HT, Peng KW, Ji ZH, Sun JH, Zhang Q, Yang XJ, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center. Eur J Surg Oncol. 2016;42(7):1024-34. doi: 10.1016/j.ejso.2016.04.053. PMID: 27179924.
  22. Alzahrani N, Ferguson JS, Valle SJ, Liauw W, Chua T, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St George Hospital, Australia. ANZ J Surg. 2016;86(11):937-41. doi: 10.1111/ans.13152. PMID: 26179296.
  23. Tan G, Chia C, Kumar M, Choo SP, Chia J, Tham CK, et al. 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary center. Int J Hyperthermia. 2017;33(3):288-94. doi: 10.1080/02656736.2016.1262064. PMID: 27855557.
  24. Narasimhan V, Pham T, Warrier S, Craig Lynch A, Michael M, Tie J, et al. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. ANZ J Surg. 2019;89(9):1035-40. doi: 10.1111/ans.14985. PMID: 30685879.
Middle East Journal of Cancer
Volume 16, Issue 4
Autumn 2025
Pages 366-371

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us